JPWO2020081636A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020081636A5 JPWO2020081636A5 JP2021521024A JP2021521024A JPWO2020081636A5 JP WO2020081636 A5 JPWO2020081636 A5 JP WO2020081636A5 JP 2021521024 A JP2021521024 A JP 2021521024A JP 2021521024 A JP2021521024 A JP 2021521024A JP WO2020081636 A5 JPWO2020081636 A5 JP WO2020081636A5
- Authority
- JP
- Japan
- Prior art keywords
- iii
- compound
- pharmaceutically acceptable
- ring
- viii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 64
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 37
- 229910052760 oxygen Inorganic materials 0.000 claims description 34
- 229910052757 nitrogen Inorganic materials 0.000 claims description 28
- 125000005842 heteroatom Chemical group 0.000 claims description 25
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 24
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 24
- 239000001301 oxygen Chemical group 0.000 claims description 24
- 229910052717 sulfur Inorganic materials 0.000 claims description 24
- 239000011593 sulfur Chemical group 0.000 claims description 24
- 229920006395 saturated elastomer Polymers 0.000 claims description 15
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 13
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 12
- 125000004429 atom Chemical group 0.000 claims description 8
- 125000002619 bicyclic group Chemical group 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 229910052805 deuterium Inorganic materials 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 239000013610 patient sample Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862746277P | 2018-10-16 | 2018-10-16 | |
| US62/746,277 | 2018-10-16 | ||
| PCT/US2019/056455 WO2020081636A1 (en) | 2018-10-16 | 2019-10-16 | Indole ahr inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022502476A JP2022502476A (ja) | 2022-01-11 |
| JPWO2020081636A5 true JPWO2020081636A5 (https=) | 2022-10-25 |
| JP2022502476A5 JP2022502476A5 (https=) | 2022-10-25 |
Family
ID=70284697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521024A Pending JP2022502476A (ja) | 2018-10-16 | 2019-10-16 | インドールａｈｒ阻害剤およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220144839A1 (https=) |
| EP (1) | EP3867253A4 (https=) |
| JP (1) | JP2022502476A (https=) |
| KR (1) | KR20210110566A (https=) |
| CN (1) | CN113272305A (https=) |
| AU (1) | AU2019360204A1 (https=) |
| BR (1) | BR112021007017A2 (https=) |
| CA (1) | CA3115711A1 (https=) |
| EA (1) | EA202190726A1 (https=) |
| IL (1) | IL282252A (https=) |
| MX (1) | MX2021004245A (https=) |
| SG (1) | SG11202103796TA (https=) |
| WO (1) | WO2020081636A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018195397A2 (en) | 2017-04-21 | 2018-10-25 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
| PT4065582T (pt) | 2019-11-26 | 2025-05-22 | Ikena Oncology Inc | Derivados polimórficos do carbazol e utilizações dos mesmos |
| KR20220125323A (ko) | 2020-01-10 | 2022-09-14 | 이케나 온콜로지, 인코포레이티드 | Ahr 억제제 및 이의 용도 |
| WO2021236717A1 (en) | 2020-05-20 | 2021-11-25 | Senda Biosciences, Inc. | Fused imidazole derivatives as ahr antagonists |
| US20230227453A1 (en) * | 2020-06-10 | 2023-07-20 | Delix Therapeutics, Inc. | Tricyclic psychoplastogens and uses thereof |
| WO2022078356A1 (zh) * | 2020-10-15 | 2022-04-21 | 山东轩竹医药科技有限公司 | 杂芳环类AhR抑制剂 |
| IL302346A (en) * | 2020-10-28 | 2023-06-01 | Ikena Oncology Inc | Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine |
| KR20230124583A (ko) | 2020-11-23 | 2023-08-25 | 이난타 파마슈티칼스, 인코포레이티드 | 신규한 스피로피롤리딘 유래 항바이러스제 |
| US12540141B2 (en) | 2020-11-23 | 2026-02-03 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| CN114456178B (zh) * | 2021-01-13 | 2023-06-02 | 北京华森英诺生物科技有限公司 | 四氢嘧啶[1,2-b]吲唑-4-胺类衍生物作为AhR抑制剂的用途及制备方法 |
| CN114805361B (zh) * | 2021-01-17 | 2024-02-20 | 上海凌达生物医药有限公司 | 一类氨基取代的芳香杂环并吡唑类化合物、制备方法和用途 |
| WO2022235605A1 (en) | 2021-05-04 | 2022-11-10 | Enanta Pharmaceuticals, Inc. | Novel macrocyclic antiviral agents |
| WO2023086352A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| WO2023086350A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
| US11919910B2 (en) | 2021-11-12 | 2024-03-05 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US11993600B2 (en) | 2021-12-08 | 2024-05-28 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
| WO2023137007A1 (en) * | 2022-01-11 | 2023-07-20 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 4,6,7-trifluoro-1h-indole-2-carboxylic acid |
| WO2023196307A1 (en) | 2022-04-05 | 2023-10-12 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| AU2023249795A1 (en) | 2022-04-08 | 2024-10-17 | Shy Therapeutics, Llc | Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| CN117624168A (zh) * | 2022-08-19 | 2024-03-01 | 德明药泰生物技术（深圳）有限公司 | 稠环杂环类化合物及其制备方法和应用 |
| AU2023377192A1 (en) | 2022-11-07 | 2025-05-22 | Kyoto University | Nitrogen-containing heterocyclic compound |
| KR20240169284A (ko) | 2023-05-24 | 2024-12-03 | 경희대학교 산학협력단 | AhR-매개 질환의 예방, 개선 또는 치료용 약학적 조성물 |
| WO2025114771A1 (en) | 2023-11-29 | 2025-06-05 | Latvian Institute Of Organic Synthesis | A new class of aryl hydrocarbon receptor antagonists and their optimisation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721356A (en) * | 1989-09-15 | 1998-02-24 | Gensia, Inc. | Orally active adenosine kinase inhibitors |
| EP1610774A4 (en) * | 2003-04-09 | 2008-07-16 | Exelixis Inc | TIE-2 MODULATORS AND METHODS OF USE |
| PE20051128A1 (es) * | 2004-02-25 | 2006-01-16 | Schering Corp | Pirazolotriazinas como inhibidores de quinasa |
| PE20100362A1 (es) * | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| JP2018525345A (ja) * | 2015-07-01 | 2018-09-06 | ノースウェスタン ユニバーシティ | 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用 |
| TW201811799A (zh) * | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
| WO2018195397A2 (en) * | 2017-04-21 | 2018-10-25 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
-
2019
- 2019-10-16 US US17/281,395 patent/US20220144839A1/en not_active Abandoned
- 2019-10-16 CN CN201980076086.7A patent/CN113272305A/zh active Pending
- 2019-10-16 EA EA202190726A patent/EA202190726A1/ru unknown
- 2019-10-16 WO PCT/US2019/056455 patent/WO2020081636A1/en not_active Ceased
- 2019-10-16 BR BR112021007017-6A patent/BR112021007017A2/pt not_active IP Right Cessation
- 2019-10-16 MX MX2021004245A patent/MX2021004245A/es unknown
- 2019-10-16 JP JP2021521024A patent/JP2022502476A/ja active Pending
- 2019-10-16 SG SG11202103796TA patent/SG11202103796TA/en unknown
- 2019-10-16 CA CA3115711A patent/CA3115711A1/en active Pending
- 2019-10-16 EP EP19873025.1A patent/EP3867253A4/en not_active Withdrawn
- 2019-10-16 AU AU2019360204A patent/AU2019360204A1/en not_active Abandoned
- 2019-10-16 KR KR1020217014753A patent/KR20210110566A/ko not_active Withdrawn
-
2021
- 2021-04-12 IL IL282252A patent/IL282252A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020081636A5 (https=) | ||
| JP2020517734A5 (https=) | ||
| RU2012132473A (ru) | Лиганд-направленная ковалентная модификация белка | |
| JP2020531461A5 (https=) | ||
| CA2789200C (en) | Pharmaceutically active disubstituted triazine derivatives | |
| CN107427521A (zh) | 细胞周期蛋白依赖性激酶的抑制剂 | |
| Fershtat et al. | Design of hetarylthiofuroxans by nucleophilic substitution of NO 2 group in nitrofuroxans | |
| JPWO2020113233A5 (https=) | ||
| Horvath-Bordon et al. | Alkalicyamelurates, M 3 [C 6 N 7 O 3]· x H 2 O, M= Li, Na, K, Rb, Cs: UV-luminescent and thermally very stable ionic tri-s-triazine derivatives | |
| ES2210234T3 (es) | 3-fenil-5-piridil triazoles y su empleo como insecticidas. | |
| KR20170034391A (ko) | 약물 내성 암의 치료에서 사용하기 위한 지방산 신타제 억제제 | |
| US5294715A (en) | Acridine-intercalator based hypoxia selective cytotoxins | |
| ES2568475T3 (es) | Cristales de derivado de morfinano y procedimiento para producir los mismos | |
| BRZOZOWSKI | DRUG SYNTHESIS | |
| BR112013016028B1 (pt) | Oxindóis substituídos por triazinila, seus usos e seu processo de produção | |
| Boothe et al. | Synthesis of pteroylglutamic acid. IV | |
| Kony et al. | SYNTHESIS OF OCTAWDRO-2, s-BIS (NITROIMIN0) IMIDAZO | |
| Mohammed | SYNTHESIS, AND BIOLOGICAL EVALUATION OF NEWLY SUNTHESIZED TRIAZOLOTRIAZINES AND TRIAZOLOTRAIZINES DERIVATIVES. | |
| Sasaki et al. | Synthesis of bridgeheaded nitrogen systems. s‐triazolo [4, 3‐b]‐as‐triazine, s‐triazolo [4, 3‐d]‐as‐triazine and s‐triazolo [3, 4‐b]‐1, 3, 4‐Thiadiazole ring systems | |
| KAUR | DERIVATIZATION OF TRIAZINES AND THEIR EVALUATION AS ANTIFUNGAL AGENTS | |
| Chapyshev | Recent progress in the chemistry of polyazidoazines | |
| Kochergin et al. | Synthesis of 2-amino-6-(nitroimidazolyl) thiopurines | |
| Nord et al. | Interaction of aryl tetrazolones with anions: proton transfer vs. hydrogen bonding | |
| Nassar et al. | Synthesis, reactivity and antitumor activity of some new pyrazolo [3, 4-d] pyrimidine and their triazole derivatives | |
| Dabaeva et al. | Synthesis and coronary vasodilating activity of 1-aminopyrazolo [3, 4-b] pyridines with fused tetrahydropyran (-thiopyran) and piperidine rings |